Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $447,600.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 10,000 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.76, for a total value of $447,600.00. Following the completion of the transaction, the insider now directly owns 95,034 shares in the company, valued at approximately $4,253,721.84. This represents a 9.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Catriona Yale also recently made the following trade(s):

• On Wednesday, March 12th, Catriona Yale sold 614 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.88, for a total value of $27,556.32.
• On Tuesday, February 18th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $49.87, for a total value of $498,700.00.

Akero Therapeutics Price Performance

Akero Therapeutics stock opened at $44.66 on Friday. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $3.56 billion, a PE ratio of -11.91 and a beta of -0.19. Akero Therapeutics, Inc. has a 12 month low of $17.86 and a 12 month high of $58.40. The stock has a 50-day moving average price of $43.53 and a two-hundred day moving average price of $34.28.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). Analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Morgan Stanley reaffirmed an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Citigroup upped their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Canaccord Genuity Group increased their target price on Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. UBS Group increased their target price on Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Finally, Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Akero Therapeutics currently has an average rating of “Buy” and a consensus target price of $76.29.

Hedge Funds Weigh In On Akero Therapeutics

Large investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in shares of Akero Therapeutics in the fourth quarter valued at about $41,000. Sterling Capital Management LLC increased its stake in shares of Akero Therapeutics by 764.3% in the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock valued at $50,000 after buying an additional 1,582 shares during the period. Quarry LP acquired a new stake in shares of Akero Therapeutics in the fourth quarter valued at about $83,000. Summit Investment Advisors Inc. increased its stake in shares of Akero Therapeutics by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock valued at $197,000 after buying an additional 450 shares during the period. Finally, Summit Financial Wealth Advisors LLC acquired a new stake in shares of Akero Therapeutics in the third quarter valued at about $205,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.